Table 1.
Baseline Characteristics
| Variable | Included in study, N=2931 | Excluded in study, N=1432 | P Value |
|---|---|---|---|
| Age, yrs (mean, 95% CI) | 40.93 (40.6 – 41.3) | 43.35 (42.8 – 43.9) | <0.001 |
| Race, N (%) | 0.143 | ||
| African American | 140 (47.8) | 79 (55.2) | |
| White | 153 (52.2) | 64 (44.8) | |
| BMI, kg/m2 (N, %) | 0.295 | ||
| ≥30 | 108 (37.0) | 61 (42.7) | |
| <30 | 184 (63.0) | 82 (57.3) | |
| Smoker (N, %) | 110 (37.5) | 56 (39.2) | 0.754 |
| AMH (ng/mL)3 | 0.93 (0.84 – 1.03) | 0.18 (0.15 – 0.22) | <0.001 |
| FSH (mIU/mL)3 | 6.49 (6.23 – 6.76) | 10.53 (9.45 – 11.74) | <0.001 |
| Inhibin b (pg/mL)3 | 76.60 (71.9 – 81.5) | 39.22 (34.6 – 44.5) | <0.001 |
| Estradiol (pg/mL)3 | 36.1 (33.9 – 38.35) | 30.9 (27.1 – 35.2) | 0.048 |
1
Study participants had a detectable AMH level (≥0.20 ng/mL) at their first measurement and at least one follow-up measure of AMH in order to define a slope (rate of change).
2
The excluded women were enrolled in the randomly-identified cohort but did not have an AMH slope due to an undetectable AMH at baseline or not having at least 1 follow-up measure of AMH to calculate the slope.
3
Hormone values are the geometric mean with 95% confidence interval at baseline.